Combination of intralesional verapamil and oral antioxidants for Peyronie's disease: A prospective, randomised controlled study

Andrologia

Volumn 46, Issue 8, 2014, Pages 936-942

  Favilla V , ^a   Russo, G I ^a   Privitera, S ^a   Castelli, T ^a   Madonia, M ^b   La Vignera, S ^a   Condorelli, R ^a   Calogero, A E ^a   Farina, F P ^b   Cimino, S ^a   Morgia, G ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBENZOIC ACID; ALPHA TOCOPHEROL; ANTHOCYANIN; ANTIOXIDANT; DAMIANA; ISOFLAVONE DERIVATIVE; MUIRA PUAMA; PLANT MEDICINAL PRODUCT; PROPOLIS; SOYBEAN OIL; UNCLASSIFIED DRUG; VERAPAMIL; CALCIUM CHANNEL BLOCKING AGENT;

ADULT; AGED; ARTICLE; AVOCADO; CLINICAL EVALUATION; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PEYRONIE DISEASE; RANDOMIZED CONTROLLED TRIAL; SEXUAL SATISFACTION; TABLET; TREATMENT DURATION; VISUAL ANALOG SCALE; INTRALESIONAL DRUG ADMINISTRATION; PENILE INDURATION; PROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIOXIDANTS; CALCIUM CHANNEL BLOCKERS; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; PENILE INDURATION; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VERAPAMIL; YOUNG ADULT;

EID: 84923858271     PISSN: 03034569     EISSN: 14390272     Source Type: Journal    
DOI: 10.1111/and.12178     Document Type: Article

References (29)

1. Anderson MS, Shankey TV, Lubrano T, Mulhall JP (2000) Inhibition of Peyronie's plaque fibroblast proliferation by biologic agents. Int J Impot Res 12(Suppl 3):S25-S31.
2. Cimino S, Sortino G, Favilla V, Castelli T, Madonia M, Sansalone S, Russo GI, Morgia G (2012) Polyphenols: key issues involved in chemoprevention of prostate cancer. Oxid Med Cell Longev 2012:632959.
3. El-Sakka AI, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF (1997) Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 158:1391-1394.
4. Favilla V, Cimino S, Castelli T, Madonia M, Barbagallo I, Morgia G (2010) Relationship between lower urinary tract symptoms and serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia. BJU Int 106:1700-1703.
5. Garaffa G, Sansalone S, Ralph DJ (2013) Penile reconstruction. Asian J Androl 15:16-19.
6. Gholami SS, Gonzalez-Cadavid NF, Lin CS, Rajfer J, Lue TF (2003) Peyronie's disease: a review. J Urol 169:1234-1241.
7. Hatzimouratidis K, Eardley I, Giuliano F, Hatzichristou D, Moncada I, Salonia A, Vardi Y, Wespes E (2012) EAU guidelines on penile curvature. Eur Urol 62:543-552.
8. Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S (2002) A retrospective review of 307 men with Peyronie's disease. J Urol 168:1075-1079.
9. Kelami A (1983) Classification of congenital and acquired penile deviation. Urol Int 38:229-233.
10. LaRochelle JC, Levine LA (2007) A Survey of primary-care physicians and urologists regarding Peyronie's disease. J Sex Med 4:1167-1173.
11. Levine LA, Goldman KE, Greenfield JM (2002) Experience with intraplaque injection of verapamil for Peyronie's disease. J Urol 168:621-625.
12. Loreto C, Barbagli G, Djinovic R, Vespasiani G, Carnazza ML, Miano R, Musumeci G, Sansalone S (2011) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its death receptor (DR5) in Peyronie's disease. A biomolecular study of apoptosis activation. J Sex Med 8:109-115.
13. Morgia G, Cimino S, Favilla V, Russo GI, Squadrito F, Mucciardi G, Masieri L, Minutoli L, Grosso G, Castelli T (2013) Effects of Serenoa repens, selenium and lycopene (Profluss(R)) on chronic inflammation associated with benign prostatic hyperplasia: results of "FLOG" (Flogosisand Profluss in Prostatic and Genital Disease), a multicentre Italian study. Int Braz J Urol 39:214-221.
14. Mulhall JP, Anderson MS, Lubrano T, Shankey TV (2002) Peyronie's disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res 14:397-405.
15. Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, Davis R, Hellstrom W (2004) Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol 171:2350-2353.
16. Muller A, Mulhall JP (2009) Peyronie's disease intervention trials: methodological challenges and issues. J Sex Med 6:848-861.
17. Musitelli S, Bossi M, Jallous H (2008) A brief historical survey of "Peyronie's disease". J Sex Med 5:1737-1746.
18. O'Leary KA, de Pascual-Tereasa S, Needs PW, Bao YP, O'Brien NM, Williamson G (2004) Effect of flavonoids and vitamin E on cyclooxygenase-2 (COX-2) transcription. Mutat Res 551:245-254.
19. Paulis G, Brancato T (2012) Inflammatory mechanisms and oxidative stress in Peyronie's disease: therapeutic "rationale" and related emerging treatment strategies. Inflamm Allergy Drug Targets 11:48-57.
20. Paulis G, Cavallini G, Brancato T, Alvaro R (2012a) Peironimevplus(R) in the treatment of Chronic Inflammation of Tunica Albuginea (Peyronie's Disease). Results of a controlled study. Inflamm Allergy Drug Targets 11:48-57.
21. Paulis G, D'Ascenzo R, Nupieri P, De Giorgio G, Orsolini G, Brancato T, Alvaro R (2012b) Effectiveness of antioxidants (propolis, blueberry, vitamin E) associated with verapamil in the medical management of Peyronie's disease: a study of 151 cases. Int J Androl 35:521-527.
22. Paulis G, Brancato T, D'Ascenzo R, De Giorgio G, Nupieri P, Orsolini G, Alvaro R (2013) Efficacy of vitamin E in the conservative treatment of Peyronie's disease: legend or reality? A controlled study of 70 cases. Andrology 1:120-128.
23. Roth M, Eickelberg O, Kohler E, Erne P, Block LH (1996) Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci USA 93:5478-5482.
24. Safarinejad MR (2004) Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study. Int J Impot Res 16:238-243.
25. Sansalone S, Garaffa G, Djinovic R, Egydio P, Vespasiani G, Miano R, Loreto C, Ralph DJ (2012) Simultaneous penile lengthening and penile prosthesis implantation in patients with Peyronie's disease, refractory erectile dysfunction, and severe penile shortening. J Sex Med 9:316-321.
26. Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U (2001) The prevalence of Peyronie's disease: results of a large survey. BJU Int 88:727-730.
27. Sebastiano C, Vincenzo F, Tommaso C, Giuseppe S, Marco R, Ivana C, Giorgio R, Massimo M, Giuseppe M (2012) Dietary patterns and prostatic diseases. Front Biosci (Elite Ed) 4:195-204.
28. Sommer F, Schwarzer U, Wassmer G, Bloch W, Braun M, Klotz T, Engelmann U (2002) Epidemiology of Peyronie's disease. Int J Impot Res 14:379-383.
29. Tunuguntla HS (2001) Management of Peyronie's disease-a review. World J Urol 19:244-250.